B. J. Marshall and J. R. Warren, “Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration,” The Lancet, vol. 1, no. 8390, pp. 1311–1314, 1984.
[2]
B. J. Marshall, J. A. Armstrong, D. B. McGechie, and R. J. Glancy, “Attempt to fulfil Koch's postulates for pyloric campylobacter,” Medical Journal of Australia, vol. 142, no. 8, pp. 436–439, 1985.
[3]
“NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease,” The Journal of the American Medical Association, vol. 272, no. 1, pp. 65–69, 1994.
[4]
P. Malfertheiner, “Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report,” Gut, vol. 41, no. 1, pp. 8–13, 1997.
[5]
P. Malfertheiner, F. Mégraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 2, pp. 167–180, 2002.
[6]
N. J. Talley, V. Meineche-Schmidt, P. Paré et al., “Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies),” Alimentary Pharmacology and Therapeutics, vol. 12, no. 11, pp. 1055–1065, 1998.
[7]
A. L. Blum, R. Arnold, M. Stolte, M. Fischer, and H. R. Koelz, “Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group,” Gut, vol. 47, no. 4, pp. 473–480, 2000.
[8]
S. Tefera, J. G. Hatlebakk, and A. Berstad, “The effect of Helicobacter pylori eradication on gastro-oesophageal reflux,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 7, pp. 915–920, 1999.
[9]
H. J. O'Connor, “Review article: Helicobacter pylori and gastro-oesophageal reflux disease—clinical implications and management,” Alimentary Pharmacology and Therapeutics, vol. 13, no. 2, pp. 117–127, 1999.
[10]
J. P. Gisbert, J. M. Pajares, and J. Valle, “Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review,” Helicobacter, vol. 4, no. 1, pp. 58–66, 1999.
[11]
P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007.
[12]
B. Annibale, M. Marignani, B. Monarca et al., “Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis,” Annals of Internal Medicine, vol. 131, no. 9, pp. 668–672, 1999.
[13]
M. Franchini and D. Veneri, “Helicobacter pylori-associated immune thrombocytopenia,” Platelets, vol. 17, no. 2, pp. 71–77, 2006.
[14]
W. Ye, M. Held, J. Lagergren et al., “Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia,” Journal of the National Cancer Institute, vol. 96, no. 5, pp. 388–396, 2004.
[15]
A. Ford and P. Moayyedi, “How can the current strategies for Helicobacter pylori eradication therapy be improved?” Canadian Journal of Gastroenterology, vol. 17, supplement B, pp. 36B–40B, 2003.
[16]
F. Megraud, “Update on therapeutic options for Helicobacter pylori-related diseases,” Current Infectious Disease Reports, vol. 7, no. 2, pp. 115–120, 2005.
[17]
P. Malfertheiner, F. Megraud, C. O'Morain, et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, pp. 646–664, 2012.
[18]
L. Lundell, N. Havu, P. Miettinen et al., “Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 5, pp. 639–647, 2006.
[19]
R. Deguchi, M. Matsushima, T. Suzuki et al., “Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy,” Journal of Gastroenterology, vol. 44, no. 7, pp. 713–716, 2009.
[20]
T. Shimoyama, C. Kato, M. Kodama, I. Kobayashi, and Y. Fukuda, “Applicability of a monoclonal antibody-based stool antigen test to evaluate the results of Helicobacter pylori eradication therapy,” Japanese Journal of Infectious Diseases, vol. 62, no. 3, pp. 225–227, 2009.
[21]
D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 8, pp. 556–563, 2007.
[22]
A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, “Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 2, pp. 109–118, 2009.
